On November 19, 2025 Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, reported it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session will feature leading experts in gastrointestinal oncology and patient advocates discussing progress with the BOT/BAL program, emerging clinical insights, and the evolving treatment landscape for colorectal cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The session will be moderated by Garo Armen, PhD, Founder, Chairman, and CEO, and will conclude with a live Q&A. Questions can be submitted in advance to [email protected]
Featured Topics and Speakers
Role of Immuno-Oncology in Colorectal Cancer
Christopher Lieu, MD, FASCO, Professor of Medicine; Sohrab Amini, MD, FACS Endowed Chair in Pancreatic Cancer Research; Associate Director for clinical Research, University of Colorado Cancer Center
Dr. Christopher Lieu will discuss the evolving role of immuno-oncology in colorectal cancer, and how expectations for MSS disease are shifting with emerging mechanisms and combination approaches. He will also highlight select clinical insights from his practice, including a notable case that illustrates the potential for deep and durable responses.
Global Phase 3 BATTMAN Study (CO.33) Update
Jonathan Loree, MD; Medical Oncologist, BC Cancer; Associate Professor, University of British Columbia; Senior Investigator, Canadian Cancer Trials Group (CCTG); Co-Chair, NCI Colon Cancer Task Force
Dr. Jonathan Loree will provide an update on the global Phase 3 BATTMAN study, including site engagement, operational readiness, and early feedback from investigators supporting strong trial momentum heading into 2026.
A Caregiver & Physician Perspective: Early-Onset CRC and Paving a New Path Forward
Benny Johnson, DO; Senior Medical Director, Agenus; Former Assistant Professor, GI Medical Oncology MD Anderson Cancer Center
Dr. Johnson will share his family’s experience navigating early-onset colorectal cancer from diagnosis through treatment decision-making, including the choice to participate in a clinical trial evaluating BOT/BAL. Their conversation will highlight the lived realities behind clinical innovation and the importance of expanding patient-centered options for the growing early-onset population, from the perspective of a family impacted by CRC.
Stakeholder Briefing Details:
Registration Link: View Source
Live webcast link will be provided once registration is completed.
Have a Question? Submit them in advance to [email protected]
This session is the third in Agenus’ 2025 Stakeholder Briefing Webcast Series, following the October event highlighting new pan-tumor data from ESMO (Free ESMO Whitepaper) 2025 and perspectives on the French AAC program. Webcasts will resume in 2026, continuing the dialogue on BOT/BAL’s progress and corporate milestones.
(Press release, Agenus, NOV 19, 2025, View Source [SID1234660096])